Gut Liver.  2014 Nov;8(6):648-654. 10.5009/gnl13406.

High Expression of Aldo-Keto Reductase 1B10 Is an Independent Predictor of Favorable Prognosis in Patients with Hepatocellular Carcinoma

• Ha SY
• Song DH
• Lee JJ
• Lee HW
• Cho SY
• Park CK

• KMID: 2070083
• DOI: http://doi.org/10.5009/gnl13406

Abstract

BACKGROUND/AIMS
Upregulation of aldo-keto reductase 1B10 (AKR1B10) through the mitogenic activator protein-1 signaling pathway might promote hepatocarcinogenesis and tumor progression. The goal of this study was to evaluate the prognostic significance of AKR1B10 protein expression in patients with hepatocellular carcinoma after surgery.
METHODS
A tissue microarray was used to detect the expression level of AKR1B10 protein in tumors from 255 patients with hepatocellular carcinoma who underwent curative hepatectomy. The impact of AKR1B10 expression on the survival of patients was analyzed. The median follow-up period was 119.8 months.
RESULTS
High AKR1B10 protein expression was observed in 125 of the 255 patients with hepatocellular carcinoma (49.0%). High AKR1B10 expression was significantly associated with a lack of invasion of the major portal vein (p=0.022), a lack of intrahepatic metastasis (p=0.010), lower the American Joint Committee on Cancer T stage (p=0.016), lower the Barcelona Clinic Liver Cancer stage (p=0.006), and lower alpha-fetoprotein levels (p=0.020). High AKR1B10 expression was also correlated with a lack of early recurrence (p=0.022). Multivariate analyses of survival revealed that intrahepatic metastases and lower albumin levels were independent predictors of both shorter recurrence-free survival and shorter disease-specific survival. High AKR1B10 expression was an independent predictor of both longer recurrence-free survival (p=0.024) and longer disease-specific survival (p=0.046).
CONCLUSIONS
High AKR1B10 protein expression might be useful as a marker of a favorable prognosis in patients with hepatocellular carcinoma after curative hepatectomy.

Keyword

AKR1B10; Carcinoma, hepatocellular; Survival

MeSH Terms

Adolescent
Adult
Aged
Aldehyde Reductase/*metabolism
Carcinoma, Hepatocellular/*metabolism/surgery
Disease-Free Survival
Female
Hepatectomy
Humans
Immunohistochemistry
Liver Neoplasms/*metabolism/surgery
Male
Middle Aged
Prognosis
Tumor Markers, Biological/*metabolism
Young Adult
Tumor Markers, Biological
Aldehyde Reductase